NEWS DETAIL

In Collaboration with Atara, Memorial Sloan Kettering Cancer Center (MSK) Has Enrolled Several Patients into the Open-Label, Single-Arm Phase 1 Clinical Study of ATA2271

In collaboration with Atara, Memorial Sloan Kettering Cancer Center (MSK) has enrolled several patients into the open-label, single-arm Phase 1 clinical study of ATA2271, the Company's second-generation autologous CAR T therapy targeting mesothelin (MSLN) that incorporates for the first time both a novel 1XX co-stimulatory domain for improving functional persistence and a PD-1 DNR (dominant-negative programmed death-1 receptor) for intrinsic check-point inhibition for the treatment of advanced mesothelioma

•  Atara and MSK expect to present first Phase 1 data for ATA2271 in Q4 2021

 

Source: Atara Biotherapeutics, Inc. 2020 Annual Report